Eli Lilly manufactures the ingredients for Mounjaro and its diabetes drug Zepbound in Kinsale, Co Cork. Photograph: George Frey/Bloomberg via Getty Images
Last month, Eli Lilly’s weight-loss drug Mounjaro became India’s top-selling drug, overtaking GSK’s widely used antibiotic Augmentin.
Mounjaro was only launched in India in March, a testimony to the explosive demand for these medications.
Last month it outsold rival weight-loss drug Wegovy (produced by Novo Nordisk) by a ratio of 10 to one.
[ Eli Lilly’s blockbuster weight-loss drugs drive surge in Irish exportsOpens in new window ]
India – with a population of more than 1.4 billion – has become a key battleground in the global weight-loss market. Analysts predict the market could generate €130 billion a year by the end of the decade.
This little snippet of news and its importance for Ireland went larg
Continue Reading on The Irish Times
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.